Following the company’s fourth quarter results, RBC analyst Maxim Matushansky has retained his “Outperform” rating on Calian Group (Calian Group Stock Quote, Chart, News, Analysts, Financials TSX:CGY), though he has lowered his expectation slightly.
On November 27, CGY reported its Q4, 2023 results. The company posted Adjusted EBITDA of $20-million on revenue of $176-million, a topline that was up ten per cent over the same period a year prior.
“We finished the year with a record quarter as revenues, gross margin and adjusted EBITDA reached new historical highs,” CEO Kevin Ford said. “In FY23 we generated double-digit revenue growth with all four segments contributing. Our adjusted EBITDA remained flat. With two recent acquisitions and adjustments in our operating costs, we are poised to see continued increase in our profitability. Given the ongoing robust demand for our products and services, the contribution from recent acquisitions and the benefits from our restructuring plan, we are confident in our ability to post another record year. At the midpoint of our guidance range this translates into revenue and adjusted EBITDA growth of 15 per cent and 32 per cent, respectively, over FY23.”
As reported in the Globe and Mail, Matushansky has lowered his price target on Calian Group from $70.00 to $65.00. The stock closed November 28 at $52.08.
Trulieve Cannabis (Trulieve Cannabis Stock Quote, Chart, News, Analysts, Financials CSE:TRUL) delivered a strong start to fiscal 2025, beating high-end… [Read More]
Green Thumb Industries (Green Thumb Industries Stock Quote, Chart, News, Analysts, Financials CSE:GTII) delivered a steady first quarter and remains… [Read More]
5N Plus (5N Plus Stock Quote, Chart, News, Analysts, Financials TSX:VNP) blew past expectations in the first quarter of 2025,… [Read More]
Kinaxis (Kinaxis Stock Quote, Chart, News, Analysts, Financials TSXV:KXS) delivered first-quarter results that met expectations, with record adjusted EBITDA and… [Read More]
Paradigm Capital analyst Scott McAuley is maintaining a "Buy" rating and $2.30 target on Spectral Medical (Spectral Medical Stock Quote,… [Read More]
Ballard Power’s (Ballard Power Stock Quote, Chart, News, Analysts, Financials NASDAQ:BLDP) disappointing Q1 2025 results prompted Roth Capital Partners analyst… [Read More]